Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
Author:
Affiliation:
1. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;
2. Children’s Healthcare of Atlanta, Atlanta, GA; and
3. Department of Radiology, Emory University School of Medicine, Atlanta, GA
Publisher
American Society of Hematology
Subject
Hematology
Link
https://ashpublications.org/bloodadvances/article-pdf/6/10/3058/1897675/advancesadv2021006535.pdf
Reference15 articles.
1. How I manage patients with Fanconi anaemia;Dufour;Br J Haematol.,2017
2. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities;Al Hamed;Bone Marrow Transplant.,2020
3. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT;Rasche;Bone Marrow Transplant.,2014
4. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice;Allen;Clin Transplant.,2019
5. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation;Uhlin;Haematologica.,2014
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?;Bone Marrow Transplantation;2023-11-25
2. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review;Transplant Immunology;2023-10
3. Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder;Cancers;2022-12-01
4. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment;Current Opinion in Oncology;2022-07-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3